Glivec receives FDA priority review as first therapy to reduce recurrence of gastrointestinal stromal tumors after surgery

in
  • Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Glivec after surgery are basis for FDA, EMEA, Swissmedic filings



  • Historically, one in two patients experienced recurrence of GIST after surgery



  • Regulatory submissions reflect continued commitment to bringing new therapeutic approaches to patients with rare diseases